ArticleAntimicrobial agents and chemotherapy2015
Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Modulating Micrococcal Nuclease-Triggered Antibiotic Releases for One-Stage Revisions ofACS infectious diseases · 2026Article
- Small-colony variants of Staphylococcus aureus: hidden threat in chronic and recurrent infections.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Pharmacodynamics of aztreonam/ceftazidime/avibactam and polymyxin B versus New Delhi MBL-producing Acinetobacter baumannii.JAC-antimicrobial resistance · 2025Article
- Adjuvant intra-articular vancomycin for recalcitrant Staphylococcal prosthetic joint infections of the knee.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024Observational
- Detection, Identification and Diagnostic Characterization of the Staphylococcal Small Colony-Variant (SCV) Phenotype.Antibiotics (Basel, Switzerland) · 2023Review
- Characteristics of Staphylococcus aureus small colony variants isolated from wound specimen of a tertiary care hospital in China.Journal of clinical laboratory analysis · 2022Article
- Development and current use of local antibiotic carriers in spondylodiscitis : Pilot study on reduction of duration of systemic treatment.Der Orthopade · 2020Article
- Resistance Evolution Against Antimicrobial Peptides inFrontiers in microbiology · 2020Article
- Bacterial biofilm formation is variably inhibited by different formulations of antibiotic-loaded bone cement in vitro.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2019Article
- Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.The Journal of antimicrobial chemotherapy · 2017Article
- High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.The Journal of antimicrobial chemotherapy · 2017Article
- Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.International journal of antimicrobial agents · 2016Article
- Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.Clinical microbiology reviews · 2016Review
- Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.Antimicrobial agents and chemotherapy · 2015Article
- Phenotypic and Genotypic Characteristics of Small Colony Variants and Their Role in Chronic Infection.Microbiology insights · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Staphylococcus aureus small-colony variants (SCVs) often persist despite antibiotic therapy. Against a 10(8)-CFU/ml methicillin-resistant S. aureus (MRSA) (strain COL) population of which 0%, 1%, 10%, 50%, or 100% was an isogenic hemB knockout (Ia48) subpopulation displaying the SCV phenotype, vancomycin achieved maximal reductions of 4.99, 5.39, 4.50, 3.28, and 1.66 log10 CFU/ml over 48 h. Vancomycin at ≥16 mg/liter shifted a population from 50% SCV cells at 0 h to 100% SCV cells at 48 h, which was well characterized by a Hill-type model (R2>0.90).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.